Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

@article{Wu2017DacomitinibVG,
  title={Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.},
  author={Y. Wu and Y. Cheng and X. Zhou and K. H. Lee and K. Nakagawa and S. Niho and F. Tsuji and R. Linke and R. Rosell and J. Corral and M. R. Migliorino and A. Płużański and E. Sbar and T. Wang and Jane Liang White and S. Nadanaciva and R. Sandin and T. Mok},
  journal={The Lancet. Oncology},
  year={2017},
  volume={18 11},
  pages={
          1454-1466
        }
}
  • Y. Wu, Y. Cheng, +15 authors T. Mok
  • Published 2017
  • Medicine
  • The Lancet. Oncology
  • BACKGROUND Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC). METHODS In this international, multicentre, randomised, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    This is a multi-center, single-arm, open-label, Phase 2 clinical study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases.  
    ConditionsDacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    TKIs therapy is the first-line treatment of patients with EGFR mutation advanced NSCLC.However, some patients have poor prognosis of drug resistance in the early stage. The dynamic… Expand
    ConditionsEGFR Gene Mutation, Non-small Cell Lung Cancer
    InterventionDrug
    Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer
    • 2

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 33 REFERENCES